Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
- W. Cushman, G. Evans, +14 authors F. Ismail-Beigi
- Medicine
- The New England journal of medicine
- 29 April 2010
BACKGROUND
There is no evidence from randomized trials to support a strategy of lowering systolic blood pressure below 135 to 140 mm Hg in persons with type 2 diabetes mellitus. We investigated… Expand
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
- S. Lippman, E. Klein, +30 authors C. Coltman
- Medicine
- JAMA
- 7 January 2009
CONTEXT
Secondary analyses of 2 randomized controlled trials and supportive epidemiologic and preclinical data indicated the potential of selenium and vitamin E for preventing prostate cancer.
… Expand
Effects of combination lipid therapy in type 2 diabetes mellitus.
- H. Ginsberg, M. Elam, +14 authors R. Byington
- Medicine
- The New England journal of medicine
- 29 April 2010
BACKGROUND
We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2… Expand
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
- W. Boden, J. Probstfield, +6 authors W. Weintraub
- Medicine
- The New England journal of medicine
- 15 December 2011
BACKGROUND
In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin… Expand
Effects of intensive glucose lowering in type 2 diabetes.
- H. Gerstein, M. Miller, +10 authors W. Friedewald
- Medicine
- The New England journal of medicine
- 12 June 2008
BACKGROUND
Epidemiologic studies have shown a relationship between glycated hemoglobin levels and cardiovascular events in patients with type 2 diabetes. We investigated whether intensive therapy to… Expand
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
- M. Pfeffer, B. Claggett, +13 authors J. Tardif
- Medicine
- The New England journal of medicine
- 2 December 2015
BACKGROUND
Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We… Expand
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
- D. Gordon, J. Probstfield, +6 authors H. Tyroler
- Medicine
- Circulation
- 1989
The British Regional Heart Study (BRHS) reported in 1986 that much of the inverse relation of high-density lipoprotein cholesterol (HDLC) and incidence of coronary heart disease was eliminated by… Expand
Basal insulin and cardiovascular and other outcomes in dysglycemia.
- H. Gerstein, J. Bosch, +9 authors S. Yusuf
- Medicine
- The New England journal of medicine
- 26 July 2012
BACKGROUND
The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested.
METHODS
We… Expand
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- J. Eikelboom, S. Connolly, +46 authors S. Yusuf
- Medicine
- The New England journal of medicine
- 27 August 2017
BACKGROUND We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS In this double‐blind… Expand
Spironolactone for heart failure with preserved ejection fraction.
- B. Pitt, M. Pfeffer, +20 authors S. Mckinlay
- Medicine
- The New England journal of medicine
- 9 April 2014
BACKGROUND
Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in… Expand